Evidence map›Paper›PMID 39838121›Full record

ArticleMedical oncology (Northwood, London, England)2025

The impact of apoptosis-inducing MAPK and glycolytic pathways modulated by Aloe vera and royal jelly in lung and colorectal cancer.

Tuğba Kul Köprülü, Bahar Gezer, Burçin Erkal Çam

Abstract read
In one paragraph

Article in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Tuğba Kul KöprülüExperimental Medicine Application and Research Center, Validebağ Research Park, University of Health Sciences, Altunizade, Kalfaçeşme Street, Üsküdar, 34662, İstanbul, Turkey. tugbakul.koprulu@sbu.edu.tr.ORCID http://orcid.org/0000-0001-9451-5715
Bahar GezerDepartment of Molecular Medicine, Hamidiye Institute of Health Sciences, University of Health Sciences, 34668, İstanbul, Turkey.ORCID http://orcid.org/0000-0002-2054-0034
Burçin Erkal ÇamDepartment of Molecular Biology and Genetics, Faculty of Arts and Sciences, Yıldız Technical University, Esenler, İstanbul, Turkey.ORCID http://orcid.org/0000-0002-0275-5613

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung and colon cancer are among the most commonly diagnosed and fatal cancer types in the world. Due to their metastatic properties, they complicate the treatment process and pose a great threat to human health. These aggressive types of cancer are resistant to chemotherapy drugs. Therefore, it is extremely important to investigate the therapeutic effects of natural compounds. In our previous study, effective doses of Royal Jelly (RJ) (100 mg/mL) and Aloe vera (AVE) (20 µg/mL) were determined and tested separately and in combination on lung and colorectal cancer cells. Glycolytic capacities were determined using the Seahorse XFe24 Analyzer, total transcriptome profiles were sequenced using NovaSeq 6000, and BAX and BCL-2 gene levels were determined using RT-qPCR. It was seen that RJ and RJ + AVE affected glycolytic capacity and more genes in lung cancer cells. In HT29, AVE alone was seen to reduce glycolytic capacity and RJ + AVE combination was seen to reduce the expression level of genes related to cell proliferation and cycle. After RJ + AVE treatments, the apoptotic process which is triggered via MAPK pathway was found in lung cancer. Moreover, BAX levels increased and BCL-2 levels decreased both lung and colorectal cancer cells. It was observed that the combination of RJ and AVE affected the glycolysis process, cell cycle, proliferation and apoptosis on lung and colorectal cancer. In particular, the combination of RJ + AVE was found to be more effective on lung cancer.

Indexed as

AloeApoptosisColorectal NeoplasmsFatty AcidsGlycolysisLung NeoplasmsMAP Kinase Signaling SystemCell Line, TumorCell ProliferationHT29 CellsHumansRoyal JellyFatty AcidsRoyal JellyBAXBCL-2Extracellular acidification rateGlycolytic capacityMAPK signalingTranscriptome profiling

Identifiers

PMID39838121
PMCPMC11750912

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.